Ratings IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
10.44 USD -1.88% Intraday chart for IGM Biosciences, Inc. -0.10% +25.63%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
+25.63% 614M
C-
+1.10% 106B
B+
+9.29% 103B
B+
-3.00% 21.44B
B
-11.89% 22.11B
B+
-26.59% 20.99B
A-
-5.20% 19.44B
A-
-6.58% 17.6B
B
+5.83% 13.88B
C+
+7.46% 11.75B
D
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes